US4937249A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Imide derivatives and their pharmaceutical use
Assignee: Sumitomo Pharma Co Ltd
•
Filing: 1988-10-25
•
Granted: 1990-06-26
•
Expires: 2008-10-25
Abstract
Abstract A compound of the formula: ##STR1## or its acid addition salt, which is useful as a psychotic drug.
Inventors
- 👤 Fujio Antoku
- 👤 Mayumi Yoshigi
- 👤 Ikutaro Saji
- 👤 Kikuo Ishizumi
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 16:11
CPC Classifications
C; C07; C07D; C07D413/00; C07D413/14; C07D417/00; C07D417/14
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
299 words
A compound of the formula: wherein A is a carbonyl group or a sulfonyl group; B is either one of the formulas: ##STR102## (in which R 1 and R 2 are each a hydrogen atom, or either one of them is a hydrogen atom and the other is a hydroxyl group, a C 1 -C 5 alkyl group or a C 2 -C 6 alkanoyloxy group, or R 1 and R 2 are combined together to represent an oxo group, E is a methylene group, an ethylene group or an oxygen atom and the full line accompanying a broken line ( ) indicates a single bond or a double bond), ##STR103## (in which F is a methylene group or an ethylene group and R 1 , R 2 and the full line accompanying a broken line ( ) are each as defined above), ##STR104## (in which R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are each a hydrogen atom or a C 1 -C 5 alkyl group and R 1 , R 2 and the full line accompanying a broken line ( ) are each as defined above), or ##STR105## (in which R 9 and R 10 are each a C 1 -C 5 alkyl group) when A represents a carbonyl group, or B is a 1,2-phenylene group when A represents a sulfonyl group; W is a C 1 -C 6 alkylene group, a C 2 -C 6 alkenylene group, a C 2 -C 6 alkynylene group or a C 2 -C 6 alkylene group substituted with hydroxyl; and G is a hydrogen atom, a C 1 -C 5 alkyl group, a C 1 -C 5 alkoxy group, a halogen atom or a hydroxyl group, or its pharmaceutically acceptable salt.
Claim 2
Dependent Claim
299 words
A compound of the formula: wherein A is a carbonyl group or a sulfonyl group; B is either one of the formulas: ##STR102## (in which R 1 and R 2 are each a hydrogen atom, or either one of them is a hydrogen atom and the other is a hydroxyl group, a C 1 -C 5 alkyl group or a C 2 -C 6 alkanoyloxy group, or R 1 and R 2 are combined together to represent an oxo group, E is a methylene group, an ethylene group or an oxygen atom and the full line accompanying a broken line ( ) indicates a single bond or a double bond), ##STR103## (in which F is a methylene group or an ethylene group and R 1 , R 2 and the full line accompanying a broken line ( ) are each as defined above), ##STR104## (in which R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are each a hydrogen atom or a C 1 -C 5 alkyl group and R 1 , R 2 and the full line accompanying a broken line ( ) are each as defined above), or ##STR105## (in which R 9 and R 10 are each a C 1 -C 5 alkyl group) when A represents a carbonyl group, or B is a 1,2-phenylene group when A represents a sulfonyl group; W is a C 1 -C 6 alkylene group, a C 2 -C 6 alkenylene group, a C 2 -C 6 alkynylene group or a C 2 -C 6 alkylene group substituted with hydroxyl; and G is a hydrogen atom, a C 1 -C 5 alkyl group, a C 1 -C 5 alkoxy group, a halogen atom or a hydroxyl group, or its pharmaceutically acceptable salt.
Claim 3
Dependent Claim
40 words
The compound according to claim 1, wherein A is a carbonyl group and B is a group of the formula: ##STR106## (in which R 1 and R 2 are each as defined in claim 1), or its pharmaceutically acceptable salt.
Claim 4
Dependent Claim
41 words
The compound according to claim 1, wherein A is a carbonyl group and B is a group of the formula: ##STR107## (in which F, R 1 and R 2 are each as defined in claim 1), or its pharmaceutically acceptable salt.
Claim 5
Dependent Claim
52 words
The compound according to claim 1, wherein A is a carbonyl group and B is a group of the formula: ##STR108## (in which R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are each as defined in claim 1), or its pharmaceutically acceptable salt.
Claim 6
Dependent Claim
40 words
The compound according to claim 1, wherein A is a carbonyl group and B is a group of the formula: ##STR109## (in which R 9 and R 10 are each as defined in claim 1), or its pharmaceutically acceptable salt.
Claim 7
Dependent Claim
23 words
The compound according to claim 1, wherein A is a sulfonyl group and B is a 1,2-phenylene group, or its pharmaceutically acceptable salt.
Claim 8
Dependent Claim
71 words
The compound according to claim 1, wherein W is --(CH 2 ) 4 --, --CH 2 CH=CHCH 2 --, --CH 2 C=CCH 2 --, --CH 2 CH(OH)CH 2 CH 2 -- or --CH 2 CH 2 CH(OH)(CH 2 -- and G is a hydrogen atom, a C 1 -C 5 alkyl group, a C 1 -C 5 alkoxy group, a halogen atom or a hydroxyl group, or its pharmaceutically acceptable salt.
Claim 9
Dependent Claim
46 words
The compound according to claim 1, which is the one representable by the formula: ##STR110## wherein E' is a methylene group or an ethylene group and the full line accompanying a broken line ( ) is as defined in claim 1, or its pharmaceutically acceptable salt.
Claim 10
Dependent Claim
36 words
The compound according to claim 1, which is the one representable by the formula: ##STR111## wherein the full line accompanying a broken line ( ) is as defined in claim 1, or its pharmaceutically acceptable salt.
Claim 11
Dependent Claim
41 words
A pharmaceutical composition for treatment of psychosis which comprises an active ingredient a pharmaceutically effective amount of the compound (I) or its pharmaceutically acceptable acid addition salt according to claim 1, and at least one pharmaceutically acceptable inert carrier or diluent.
Claim 12
Dependent Claim
35 words
A method for treatment of psychosis which comprises administering a pharmaceutically effective amount of the compound (I) or its pharmaceutically acceptable acid addition salt according to claim 1 to a human being in need thereof.
References Cited (Backward Citations)
US4186203A
Cited
US4399145A
Cited
US4352811A
Cited
US4355037A
Cited
US4408054A
Cited
US4408053A
Cited
US4408054B1
Cited
US4411901A
Cited
US4390544A
Cited
US4524206A
Cited
US4804663A
Cited
US4812461A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-06-25 | 1993-12-25 | 1994-06-26 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-06-25 | 1997-12-25 | 1998-06-26 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-06-25 | 2001-12-25 | 2002-06-26 | $7700.00 | Window Closed / Lapsed |